Cargando…

Heterogeneity derived from (18)F‐FDG PET/CT predicts immunotherapy outcome for metastatic triple‐negative breast cancer patients

BACKGROUND: Recently, immunotherapy has been used to treat metastatic triple‐negative breast cancer (mTNBC). Basic research has indicated a relation between tumor heterogeneity and the immune response. Tumor heterogeneity derived from (18)F‐FDG PET/CT is a potential predictor of chemotherapy results...

Descripción completa

Detalles Bibliográficos
Autores principales:	Xie, Yizhao, Liu, Cheng, Zhao, Yannan, Gong, Chengcheng, Li, Yi, Hu, Shihui, Song, Shaoli, Hu, Xichun, Yang, Zhongyi, Wang, Biyun
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2022
Materias:	Clinical Cancer Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9089221/ https://www.ncbi.nlm.nih.gov/pubmed/35275444 http://dx.doi.org/10.1002/cam4.4522

Ejemplares similares

Prediction of Pretreatment 18F-FDG-PET/CT Parameters on the Outcome of First-Line Therapy in Patients with Metastatic Breast Cancer
por: Li, Yi, et al.
Publicado: (2021)

Chemotherapy Shows a Better Efficacy Than Endocrine Therapy in Metastatic Breast Cancer Patients with a Heterogeneous Estrogen Receptor Expression Assessed by (18)F-FES PET
por: Xie, Yizhao, et al.
Publicado: (2022)

Temporal Heterogeneity of HER2 Expression and Spatial Heterogeneity of (18)F-FDG Uptake Predicts Treatment Outcome of Pyrotinib in Patients with HER2-Positive Metastatic Breast Cancer
por: Gong, Chengcheng, et al.
Publicado: (2022)

Prognostic Value of Tumor Heterogeneity on 18F-FDG PET/CT in HR+HER2− Metastatic Breast Cancer Patients receiving 500 mg Fulvestrant: a retrospective study
por: Zhao, Yannan, et al.
Publicado: (2018)

Pretreatment (18)F‐FDG uptake heterogeneity may predict treatment outcome of combined Trastuzumab and Pertuzumab therapy in patients with metastatic HER2 positive breast cancer
por: Ma, Guang, et al.
Publicado: (2023)

Heterogeneity of targeted lung lesion predicts platinum-based first-line therapy outcomes and overall survival for metastatic triple-negative breast cancer patients with lung metastasis: a “PET biopsy” method
por: Xie, Yizhao, et al.
Publicado: (2019)

Evaluation of tumour heterogeneity by (18)F-fluoroestradiol PET as a predictive measure in breast cancer patients receiving palbociclib combined with endocrine treatment
por: Liu, Cheng, et al.
Publicado: (2022)

Optimal duration of prior endocrine therapy predicts the efficacy of Fulvestrant in a real‐world study for patients with hormone receptor‐positive and HER2‐negative advanced breast cancer
por: Zhao, Yannan, et al.
Publicado: (2020)

Mammary adipocytes protect triple-negative breast cancer cells from ferroptosis
por: Xie, Yizhao, et al.
Publicado: (2022)

Cisplatin shows greater efficacy than gemcitabine when combined with nab-paclitaxel in metastatic triple-negative breast cancer
por: Li, Yi, et al.
Publicado: (2019)

18-FDG PET/CT assessment of basal cell carcinoma with vismodegib
por: Thacker, Curtis A, et al.
Publicado: (2012)

Phase II trail of nab-paclitaxel in metastatic breast cancer patients with visceral metastases
por: Xie, Yizhao, et al.
Publicado: (2021)

Gross Tumor Delineation in Esophageal Cancer on MRI Compared With (18)F-FDG-PET/CT
por: Vollenbrock, Sophie E., et al.
Publicado: (2019)

(18)F-FLT and (18)F-FDG PET/CT in Predicting Response to Chemoradiotherapy in Nasopharyngeal Carcinoma: Preliminary Results
por: Qi, Shi, et al.
Publicado: (2017)

A risk stratification model for predicting brain metastasis and brain screening benefit in patients with metastatic triple‐negative breast cancer
por: Lin, Mingxi, et al.
Publicado: (2020)

The Added Value of (68)Ga-FAPI PET/CT in Patients with Head and Neck Cancer of Unknown Primary with (18)F-FDG–Negative Findings
por: Gu, Bingxin, et al.
Publicado: (2022)

Prognostic Value of Heterogeneity Index Derived from Baseline (18)F-FDG PET/CT in Mantle Cell Lymphoma
por: Liu, Fei, et al.
Publicado: (2022)

Establishment and validation of a nomogram with intratumoral heterogeneity derived from (18)F-FDG PET/CT for predicting individual conditional risk of 5-year recurrence before initial treatment of nasopharyngeal carcinoma
por: Gu, Bingxin, et al.
Publicado: (2020)

[(18)F]FDG PET/CT in the Evaluation of Melanoma Patients Treated with Immunotherapy
por: Mangas Losada, María, et al.
Publicado: (2023)

Heterogeneous Response to Immunotherapy in a Patient with Tonsillar Squamous Cell Carcinoma Assessed by (18)F-FDG PET/CT
por: Niccoli Asabella, Artor, et al.
Publicado: (2021)

Comparative study of (18)F-FDG-PET/CT imaging and serum hTERT mRNA quantification in cancer diagnosis
por: Ping, Bingqiong, et al.
Publicado: (2015)

Comparison of two regimens of weekly paclitaxel plus gemcitabine in patients with metastatic breast cancer: propensity score–matched analysis of real-world data
por: Gong, Chengcheng, et al.
Publicado: (2022)

Comparative Treatment Patterns and Outcomes of Fulvestrant versus Everolimus Plus Exemestane for Postmenopausal Metastatic Breast Cancer Resistant to Aromatase Inhibitors in Real-World Experience
por: Li, Yi, et al.
Publicado: (2020)

Heterogeneous uptake of (18)F-FDG and (18)F-PSMA-1007 PET/CT in lung cancer and lymph node metastasis
por: Hu, Yuan, et al.
Publicado: (2023)

Utilizing (18)F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer
por: Momcilovic, Milica, et al.
Publicado: (2018)

CT versus FDG-PET/CT response evaluation in patients with metastatic colorectal cancer treated with irinotecan and cetuximab
por: Skougaard, Kristin, et al.
Publicado: (2014)

Mapping heterogeneity in glucose uptake in metastatic melanoma using quantitative (18)F-FDG PET/CT analysis
por: de Heer, Ellen C., et al.
Publicado: (2018)

Stratifying triple-negative breast cancer prognosis using 18F-FDG-PET/CT imaging
por: Yue, Yong, et al.
Publicado: (2015)

(18)F-FDG PET/CT Imaging In Oncology
por: Almuhaideb, Ahmad, et al.
Publicado: (2011)

Scar Sarcoidosis on (18)F-FDG PET/CT
por: Arora, Saurabh, et al.
Publicado: (2019)

18F-FDG PET/CT and COVID-19
por: Joob, Beuy, et al.
Publicado: (2020)

A preliminary study of (18)F-FES PET/CT in predicting metastatic breast cancer in patients receiving docetaxel or fulvestrant with docetaxel
por: Gong, Chengcheng, et al.
Publicado: (2017)

Treatment after Progression on Fulvestrant among Metastatic Breast Cancer Patients in Clinical Practice: a Multicenter, Retrospective Study
por: Xie, Yizhao, et al.
Publicado: (2019)

Immunotherapy Monitoring with Immune Checkpoint Inhibitors Based on [(18)F]FDG PET/CT in Metastatic Melanomas and Lung Cancer
por: Lopci, Egesta
Publicado: (2021)

Can physiologic colonic [(18)F]FDG uptake in PET/CT imaging predict response to immunotherapy in metastatic melanoma?
por: Sachpekidis, Christos, et al.
Publicado: (2023)

Radiomic analysis for predicting prognosis of colorectal cancer from preoperative (18)F-FDG PET/CT
por: Lv, Lilang, et al.
Publicado: (2022)

Brain Metastases Unresponsive to Immunotherapy Detected by 18F-FDG-PET/CT in a Patient with Melanoma
por: Fonti, Rosa, et al.
Publicado: (2020)

(18)F‐FDG PET/CT features of immune‐related adverse events and pitfalls following immunotherapy
por: Cherk, Martin H, et al.
Publicado: (2022)

(18)F-FDG PET/CT for evaluation of metastases in nonsmall cell lung cancer on the efficacy of immunotherapy
por: Feng, Yawen, et al.
Publicado: (2023)

(68)Ga-DOTATATE and (18)F-FDG PET/CT in Paraganglioma and Pheochromocytoma: utility, patterns and heterogeneity
por: Chang, Chian A., et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_tgn55m0f3om81puj8mnj1cjlb9